Research Article

The Relationship between Plasma Soluble Receptor for Advanced Glycation End Products and Coronary Artery Disease

Table 1

The clinical data for patients.

Patient characteristicsNormal groups ()NOCA ()SAP ()ACS ()

Age (years)<0.01
Male gender ( (%))32 (52.46%)42 (72.41%)44 (72.13%)53 (71.62%)0.218
Hypertension ( (%))18 (29.51%)29 (50.00%)35 (57.38%)50 (67.57%)0.073
Diabetes ( (%))10 (16.39%)6 (10.34%)15 (24.59%)23 (31.08%)0.028
Smoking ( (%))16 (26.23%)28 (48.28%)19 (31.15%)29 (39.19%)0.176
BMI (kg/m2)0.160
History of medication
 Nitrates ( (%))18 (29.51%)23 (39.66%)36 (59.02%)47 (63.51%)0.263
 Beta blockers ( (%))20 (32.79%)26 (44.83%)30 (49.18%)35 (47.30%)0.586
 ACEIs/ARBs ( (%))8 (13.11%)14 (24.14%)12 (19.67%)13 (17.57%)0.437
 CCBs ( (%))8 (13.11%)15 (25.86%)19 (31.15%)22 (29.73%)0.161
 Aspirin ( (%))16 (26.23%)21 (36.21%)52 (85.25%)72 (97.30%)0.062
 Clopidogrel ( (%))1 (1.64%)3 (5.17%)17 (27.87%)41 (55.41%)0.024
 Statins ( (%))10 (16.39%)22 (37.93%)44 (72.13%)57 (77.03%)0.031
SBP (mmHg)<0.01
DBP (mmHg)0.031
HR (bpm)0.273
HGB (g/l)0.905
FBS (mmol/l)0.053
HbA1c (%)<0.01
TC (mmol/l)0.185
LDL-C (mmol/l)0.566
TG (mmol/l)0.562
SUA (μmol/l)0.185
Scr (μmol/l)0.474

Abbreviations: BMI: body mass index; ACEIs: angiotensin-converting enzyme inhibitors; ARBs: angiotensin receptor blockers; CCBs: calcium channel blockers; SBP: systolic blood pressure; DBP: diastolic blood pressure; HR: heart rate; HGB: hemoglobin; FBS: fasting blood glucose; HbA1c: glycosylated hemoglobin; TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TG: triglyceride; SUA: serum uric acid; Scr: serum creatinine.